Regeneron Pharmaceuticals, Inc. REGN
Composite 63/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 37/100 — a moderate mark against it.
Balance-sheet strength ranks 92/100 — a strong point in its favour. Momentum ranks 72/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour.
Income ranks 37/100 — a moderate mark against it. Valuation ranks 46/100 — a slight mark against it. Growth ranks 49/100 — a slight mark against it.
What the company does Regeneron Pharmaceuticals discovers, develops, and commercializes medicines for eye, inflammatory, cardiovascular, metabolic, neurological, infectious, rare diseases, and cancer. Key products include EYLEA for retinal diseases, Dupixent for dermatitis and asthma, and Libtayo for skin cancer. The company also partners on RNAi and CRISPR/Cas9 therapies.
Key financials Revenue grew 17% while EPS fell 5% YoY. Gross, operating, and net margins stand at 45%, 33%, and 28%, respectively. ROE is 14% and ROCE is 14%, with a strong balance sheet (debt/equity 0.09, current ratio 3.33). FCF yield is 3.7% and dividend yield is 0.5%.
Stock health Momentum is strong over 3m (13%), 6m (3%), and 12m (45%), though down 1% from its 52-week high. RSI(14) is elevated at 83, indicating overbought conditions. Quality and strength scores are 59 and 94, respectively, while growth and income scores are weaker at 40 and 39.
Price vs fair value Regeneron trades at a discount of 3.20% versus the analyst mean target of 833.54. - Recent earnings commentary highlights weaker top-line growth from partner revenues (Zacks, 2026-08-07). - Buyback and dividend focus is emphasized as fair value remains in sight (Simply Wall St., 2026-08-08). - CRISPR/cas9 partnerships (Intellia) and RNAi programs (Alnylam) remain key growth drivers (GuruFocus, 2026-08-06; MarketBeat, 2026-08-07).
Looking forward Forward P/E of 16.6x and PEG of 1.15 suggest moderate valuation relative to growth. Analysts note pipeline progress in gene-editing and RNAi, but near-term revenue volatility from partnerships may weigh on sentiment.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.